Condition: Esophageal Squamous Cell Carcinoma · Sponsor: Fudan University
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and paclitaxel as neoadjuvant treatment in participants with locally advanced esophageal squamous cell carcinoma (ESCC), and to explore treatment resistance mechanisms.
This description comes directly from the study's public registry record.
Haiquan Chen, M.D., Ph.D. · (86)13601973588 · Hqchen1@yahoo.com
Bin Li, M.D. · (86)18017319295 · lb0256327@hotmail.com
Always discuss trial participation with your own doctor first.
| Fudan University Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05281003